# US 8,569,366 B2 · Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,366 B2
- Document ID: US8569366B2
- Status: Granted
- Kind: B2
- Application number: 11/114,224
- Filed: 2005-04-26
- Published: 2006-10-26
- Granted: 2013-10-29
- Earliest claimed: 2005-04-26
- Assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
- Applicants: Antonino Amato; Menotti Calvani
- Inventors: Antonino Amato; Menotti Calvani
- Web page: https://patentgrep.com/patent/US8569366B2

## CPC

- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/7024: Esters of saccharides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.

## Claims

### Claim 1

A method for treating and relieving symptoms of diabetic neuropathy in patients affected by type 2 diabetes, comprising administering to a patient in need thereof 3 grams/day of acetyl L-carnitine, or a pharmaceutically acceptable salt thereof for at least 52 weeks in which said symptoms are selected from the group consisting of pain, paraesthesia or hyperaesthesia.

### Claim 2 (depends on 1)

The method according to claim 1, in which the pharmaceutically acceptable salt of acetyl L-carnitine is selected from the group consisting of chloride, bromide, orotate, acid aspartate, acid citrate, magnesium citrate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, mucate, acid oxalate, pamoate, acid pamoate, acid sulphate, glucose, phosphate, tartrate, acid tartrate, magnesium tartrate, 2-aminoethansulphonate, magnesium 2-ethansulphonate, choline tartrate and trichloroacetate.

### Claim 3 (depends on 1)

The method according to claim 1, in which the pharmaceutically acceptable salt of acetyl L-carnitine is a chloride salt.